AstraZeneca PLC has announced that its drug Klygefa (gefurulimab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis (gMG) in adult patients. This approval is a significant milestone for AstraZeneca, as it expands its portfolio in the rare disease sector, providing a new treatment option for patients suffering from this debilitating condition.
The approval is based on the positive results from the pivotal PREVAIL Phase III trial, which demonstrated that Klygefa met its primary endpoint, showing statistically significant and clinically meaningful improvements in patients' daily activities. The treatment is the first and only dual-binding nanobody C5 inhibitor available in the U.S., offering patients the convenience of once-weekly subcutaneous self-administration via an autoinjector.
Background
AstraZeneca, a global science-led biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription medicines in various therapeutic areas, including oncology and rare diseases. The company is incorporated in the United Kingdom and trades on the New York Stock Exchange under the ticker AZN. Its recent filings include Form 6-K submissions, with the latest dated November 16, 2026, detailing the approval of Klygefa.
What the Filing Says
The SEC filing confirms that Klygefa has been approved for the treatment of gMG in adults who are anti-acetylcholine receptor (AChR) antibody positive. The approval was supported by results from the PREVAIL Phase III trial, which indicated significant improvements in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 compared to placebo.
Impact
This approval may significantly affect patients diagnosed with gMG, a rare autoimmune disorder characterized by muscle weakness and fatigue. In the U.S., approximately 98,500 individuals are diagnosed with gMG, with 81,000 being AChR-positive. The introduction of Klygefa provides these patients with a new treatment option, enhancing their quality of life and independence.
What's Next
Regulatory submissions for Klygefa based on the PREVAIL results are currently under review in China and other countries. AstraZeneca is expected to continue expanding its reach in the rare disease market, potentially leading to more treatment options for patients globally.
Source: SEC Filing Accession Number 0001654954-26-009808
Read Next
Dominion Energy announces $1.2 billion senior notes issuance
Lakefront Biotherapeutics Launches €50 Million Share Buyback
Coca-Cola Europacific Partners Announces Share Buyback Details
Zenta Group announces $6.47 million at-the-market offering
MapLight Therapeutics Enters $100 Million Sales Agreement
Cyabra, Inc. Secures $15.6 Million in Private Placement










